Methofill Pen

Methotrexate, the active ingredient in Methofill Pen, is a folate antimetabolite presented as a prefilled injection pen for subcutaneous use. It is employed to treat autoimmune disorders, certain malignancies and ectopic pregnancy in adult patients. GNH USA supplies Methofill Pen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate acts on rapidly dividing cells and modulates immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: diminishes skin plaque formation and severity. - Certain cancers (e.g., leukemia, lymphoma): interferes with tumor cell proliferation. - Ectopic pregnancy: halts trophoblastic growth to allow non‑surgical resolution.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Mild elevation of liver enzymes. - Transient low blood cell counts. - Headache.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infection due to bone‑marrow suppression. - Acute renal failure. - Severe skin reactions such as Stevens‑Johnson syndrome. - Significant bone‑marrow aplasia leading to pancytopenia.

Methotrexate requires careful monitoring and specific safety measures. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Assess renal function: adjust dosing or avoid use if renal impairment is present. - Check complete blood count: watch for cytopenias and intervene promptly. - Avoid use in pregnancy: drug is teratogenic and contraindicated. - Ensure effective contraception: both male and female patients should use reliable methods. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes that can alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins: may reduce methotrexate efficacy. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Sulfonamides: can augment myelosuppression. - Proton pump inhibitors: may affect methotrexate absorption. - Alcohol: can exacerbate hepatic toxicity.